VACC Vaccibody AS

Nykode Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Nykode Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

OSLO, Norway, Dec. 23, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that its Chief Executive Officer Michael Engsig will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 1:30 p.m. PT / 10:30 p.m. CET.

The live and archived webcast of the presentation can be accessed in the Investors section of the Company’s website .

About Nykode Therapeutics

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies for the treatment of cancer and infectious diseases. Nykode’s modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen specific immune responses and eliciting efficacious clinical responses.

Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus (HPV)-16 induced malignancies which demonstrated positive interim efficacy and safety results from its Phase 2 trial for the treatment of cervical cancer; and VB10.NEO, an individualized cancer neoantigen vaccine, which is exclusively out-licensed to Genentech, a member of the Roche Group. Additionally, Nykode is conducting a Phase 1/2 trial with next-generation COVID-19 vaccine candidates.

The Company’s partnerships include Genentech within oncology, a multi-target collaboration with Regeneron within oncology and infectious diseases and a collaboration with Adaptive Biotechnologies for COVID-19 T cell vaccine development.

Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics may be found at

Contact for Nykode Therapeutics ASA:

Chief Business Officer, Agnete Fredriksen

Nykode Therapeutics ASA

 

Nykode Therapeutics ASA

Oslo Science Park

Gaustadalléen 21

N-0349 Oslo, Norway



EN
23/12/2022

Underlying

VACCVaccibody AS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vaccibody AS

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Georg Tigalonov-Bjerke
09/02/25 September 2, 2025 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Georg Tigalonov-Bjerke
08/27/25 August 27, 2025 1 EN
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Alexander Krämer
  • Georg Tigalonov-Bjerke
05/30/25 May 30, 2025 1 EN
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Alexander Krämer
  • Georg Tigalonov-Bjerke
05/28/25 May 28, 2025 1 EN
Geir Hiller Holom
  • Geir Hiller Holom
Free Trial
VACC VACCIBODY AS

Nykode Therapeutics (No_rec, TP: NOK) - A compromise

Today Nykode announced that Michael Engsig (CEO), Agnete Fredriksen (CSO and co-founder), and Harald Gurvin (CFO) have withdrawn their recent resignations and continue with the company. New board members have been proposed and key shareholders on the board have communicated they will propose a NOK1.00 DPS. We see the whole as a compromise.

04/16/25 April 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch